Street Calls of the Week
Investing.com - BofA Securities reiterated its Buy rating and $887.00 price target on argenx SE (NASDAQ:ARGX) on Monday, naming the company one of its top picks for 2025. The $46.4 billion market cap company has demonstrated impressive momentum, with its stock up 38.5% over the past year and currently trading near its 52-week high.
The research firm highlighted Vyvgart’s continued performance, noting that the drug has exceeded expectations more than three and a half years after its initial launch in generalized myasthenia gravis (gMG) and has demonstrated strong uptake in chronic inflammatory demyelinating polyneuropathy (CIDP).
BofA expects momentum to remain strong through 2025 and into 2026, driven by the approval of the prefilled syringe (PFS), expanding use of biologics in gMG, and further adoption in CIDP treatment.
The firm pointed to multiple potential growth catalysts, including several Phase 3 readouts for Vyvgart and additional data from the company’s maturing pipeline expected within the next 12-18 months.
BofA currently models peak sales of $6.5 billion in gMG ($447 per share) and $4.5 billion in CIDP ($280 per share) for argenx. The company maintains strong fundamentals with a healthy balance sheet, holding more cash than debt and showing robust liquidity metrics. For detailed valuation analysis and comprehensive insights, check out the full research report available on InvestingPro.
In other recent news, argenx SE has been in the spotlight following positive developments related to its drug Vyvgart. The company announced that Vyvgart met the primary endpoint in the Phase 3 ADAPT SERON study for seronegative generalized myasthenia gravis patients, marking a significant advancement in treatment options. Piper Sandler responded by raising its price target for argenx to $820, maintaining an Overweight rating. Similarly, JPMorgan reiterated its Overweight rating with a price target of EUR730, reflecting optimism about the trial results. Oppenheimer also maintained an Outperform rating, setting a price target at $778, citing the drug’s statistical significance in improving patient outcomes. RBC Capital echoed this sentiment by reiterating an Outperform rating with a price target of $850, emphasizing the meaningful benefits demonstrated by Vyvgart across all antibody status subtypes in myasthenia gravis patients. RBC Capital also initiated coverage on argenx with an Outperform rating, highlighting the company’s significant growth since Vyvgart’s initial approval. These recent developments underscore the positive reception from analysts regarding argenx’s progress and potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.